The Nrf2 pathway as a potential therapeutic target for Huntington disease A commentary on "Triterpenoids CDDO-ethyl amide and CDDO-trifluoroethyl amide improve the behavioral phenotype and brain pathology in a transgenic mouse model of Huntington disease"

Free Radic Biol Med. 2010 Jul 15;49(2):144-6. doi: 10.1016/j.freeradbiomed.2010.04.009. Epub 2010 Apr 24.

Authors

Carole Escartin¹, Emmanuel Brouillet

Affiliation

¹ CEA, DSV, I2BM, Molecular Imaging Research Center, F-92265 Fontenay-aux-Roses, France.

PMID: 20399852
DOI: 10.1016/j.freeradbiomed.2010.04.009

No abstract available

Publication types

Comment

MeSH terms

Animals
Brain / drug effects*
Brain / metabolism
Brain / pathology
Cytoprotection / drug effects
Disease Models, Animal
Drug Discovery
Heme Oxygenase-1 / biosynthesis
Heme Oxygenase-1 / genetics
Humans
Huntington Disease / drug therapy*
Huntington Disease / pathology
Huntington Disease / physiopathology
Mice
NF-E2-Related Factor 2 / genetics
NF-E2-Related Factor 2 / metabolism*
Oleanolic Acid / administration & dosage
Oleanolic Acid / analogs & derivatives*
Oxidative Stress / drug effects
Signal Transduction / drug effects
Transcriptional Activation / drug effects

Substances

2-cyano-3,12-dioxooleana-1,9(11)-dien-28-oic acid ethyl amide
NF-E2-Related Factor 2
dh404 compound
Oleanolic Acid
HMOX1 protein, human
Heme Oxygenase-1